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Abstract
The aim is to improve treatment efficacy and life quality of patients with malignant trophoblastic tumours. 
Fertility-sparing hysterotomy with uterine reconstruction was carried in 16 patients aged of 17 to 32 years: 2 cases due to 
urgent and 13 – due to planned indications.
On the basis of research, the indications for the urgent and planned fertility-sparing hysterotomy with uterine reconstruction 
in patients with malignant trophoblastic tumours were formulated. No postoperative complications. Steady remission in all cases. 
Follow up from 1 to 17 years (averaged 9.2 years).
1. Localized uterine resection with uterine reconstruction – the method of choice in malignant trophoblastic tumours surgical 
treatment.
2. Fertility-sparing hysterotomy with uterine reconstruction is only possible in centers which are experienced in the complex 
multimodality treatment of gestational trophoblastic neoplasms.
3. Basic requirement of fertility-sparing surgery is beginning adjuvant chemotherapy as soon as possible.
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1. Introduction
Gestational trophoblastic disease (GTD) comprises a spectrum of pregnancy associated disor-
ders from the pre-malignant conditions such as complete and partial hydatidiform moles (HM) through 
to the malignant choriocarcinoma (CC) and very rare placental site trophoblastic tumour/epithelioid 
trophoblastic tumour (PSTT/ETT) [1]. The malignant forms of the disease are also known as gestational 
trophoblastic tumours or neoplasia (GTN). 
Chemotherapy (CT) is the main treatment option in the most cases. Despite the fact that 
the treatment with chemotherapy (CT) has been one of the success stories of modern-day chemo-
therapy, surgery is still important for GTN patients. Surgical procedures can be divided into the 
following groups: 
1. Urgent surgical procedures:
– gynaecological surgeries;
– nongynaecological surgeries.
2. Planned surgical procedures:
– hysterectomy (with/without adnexa); 
– fertility-sparing hysterotomy with uterine reconstruction;
– excision of chemo-resistant metastasis.
3. Low-invasive techniques.
Most women with GTN are of reproductive age. For this reason, fertility becomes an im-
portant issue. Life-threatening haemorrhage can occur in women with GTN, as the uterus is usu-
ally enlarged with vascular and friable tumour inside. Traditionally, hysterectomy has been the 
main solution to this urgent disastrous condition [2]. Selective angiography and transcatheter em-
bolisation of uterine artery by gelfoamparticles is now becoming popular in intractable uterine 
bleeding [3, 4]. This technique is an attractive alternative to hysterectomy because it is minimally 
invasive and has a potential to preserve fertility [5, 6]. Successful term pregnancies have been 
reported after uterine artery embolisation in GTN. For instance, selective uterine artery emboliza-
tion in 31-year-old woman with heavy bleeding was described by Garner E. I. et. al. [7]. After two 
first-trimester spontaneous abortions, the patient successfully completed a normal pregnancy [7]. 
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13.9 % of pregnancies in a larger group (15 women) ended in miscarriage too [8]. However, small 
numbers of reported cases make it difficult to make definitive statements about obstetric outcomes. 
Uterine resection, primary closure and balloon tamponade have also been reported for the 
control of bleeding in GTN [9, 10]. These, however, are limited in selected cases only, and more 
reports are needed to establish their role.
Hysterectomy may be required for the management of excessive uterine bleeding either at 
presentation or after the onset of chemotherapy and in the management of chemoresistant disease 
localized in pelvis [11]. For refractory diseases with single focus in the uterus hysterectomy is tradi-
tionally carried out [12, 13]. According to Clark R. M. et. al. [13], complete remission was achieved 
in 75,8 % patients who underwent hysterectomy to treat chemotherapy-resistant GTN. 
The issue concerning the uterus organ-preserving surgeries has been little studied up to 
now, especially in metastatic GTN [14]. Indications, contra-indications and complications after 
such surgeries are not described in the literature.
2. Aim of research 
To improve treatment efficacy and life quality of patients with malignant trophoblastic 
tumours. 
3. Materials and methods
Fertility-sparing hysterotomy with uterine reconstruction was carried in 16 patients aged of 
17 to 32 years (Table 1). 
Table 1
General characteristics of patients
Urgent surgeries Planned surgeries Total 
Patients’ number 2 13 15
Age (average) 21,31 (26) 17–32 (25) 17–32 (25)
Prognostic score (FIGO) 2 9 8
Latent period (month) 4,5 7,4 6,8
Postoperative complications 0 0 0
Steady remission 2 13 15
Mortality 0 0 0
Follow-up (years) 17; 6 1–12 (6,3) 9,2
In 50 % of patients the pregnancy, initiating the development of GTN, was the first one. The 
latent period varied from 1 to 15 months and averaged at 6,8 months. In most patients (73,3 %) of 
study group the malignant trophoblastic tumour were initiated by HM. According to the data of 
radiological methods tumour nodes from 3 to 4 cm in diameter were found in myometrium in all 
patients. Ovarian cysts with dimensions more than 6 cm in diameter were diagnosed in 2 wom-
en (13,3 %). I stage was diagnosed in 9 women (60 %), II stage – in 1 (6,7 %), III stage – in 5 (33,3 %). 
Initially low risk disease (<6 score) group was in 7 (46,7 %) women; high-risk (>7 score) – in 
8 (53,3 %) women. 
Antitumor treatment of low risk group patients was single-agent chemotherapy with meth-
otrexate (MTX) according to the standard national protocol (50 mg/m2 intravenous weekly). For 
high-risk or chemoresistant patients – multiagent chemotherapy (EMA-CO, EMA-EP, BEP or TP).
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Urgent hysterotomy was performed in two women (not previously received special treatment). 
Planned surgical procedures in our research were carried out in 11 patients with chemotherapy- 
resistant tumours and in 2 women with relapse of disease (the patients got the primary treatment at 
regional hospitals). Restaging in patients with recurrent disease was conducted. 
The level of human chorionic gonadotrophin (hCG) in serum was determined using a sand-
wich assay – version ELISA. 
Stain in histopathology was performed using haematoxylin and eosin.
All cytometric analysis were performed on the device FACScan (Becton Dickinson), equipped 
with an argon laser with a wavelength of 488 nm. To obtain and analyze data CellQuest software for 
Mac was used. Fluorescence Measurements were made by narrowband filter 585/42 nm.
4. Results 
Urgent hysterotomy was performed on two women with GTN aged 21 and 31 year. Obstetric 
anamnesis and clinical characteristics of patients are presented in Table 2.
Table 2
Clinical characteristics of patients undergoing urgent hysterotomy
No.
Ser/No
Age, 
years Gravidity
Antecedent
pregnancy
Size of tumour 
node, cm Type of operation
Morphology of 
tumour node
Postoperative 
courses of  
chemotherapy
1 21 1 Abortion 3 Resection of uterine fundus with tumour node CC 6
2 31 3 HM 3
Hysterotomy with an exci-
sion of tumour node in the 
cornual region of the uterus
CC 7
The indications for urgent surgical procedures in these patients were:
a) In the first case – intra-abdominal bleeding as a result of penetration of the uterus by a 
tumour in the 21 year old woman, (D0A1) – a resection of uterine fundus with tumour node was 
fulfilled;
b) In the second case – intra-abdominal bleeding in a 32 years woman (D2A0). In this 
case hysterotomy with an excision of tumour node in the cornual region of the uterus was done. 
In both cases tumoral tissue invaded the whole thickness of the uterus, from endome-
trium to serosa. In the first case the tumour node, developed 3 months after abortion mor-
phologically was choriocarcinoma (CC). In the postoperative period 6 cycles of single-agent 
chemotherapy with MTX were held (the first cycle of chemotherapy was held in a 5th day of 
postoperative period). 
In the second case – the malignant GTN developed 6 months after complete HM evacuation. 
In a postoperative period 7 cycles of single-agent chemotherapy with MTX were held (the first 
cycle – in a 7s day). 
Planned surgical procedures in our research were carried out in 11 patients with chemother-
apy-resistant tumours and in 2 women with relapse of disease (the patients got the primary treat-
ment at regional hospitals). Clinical characteristics of patients undergoing planned hysterotomy are 
presented in Table 3.
According to the data of radiological methods (ultrasound with Colour Doppler and MRI) the 
tumour nodes in these patients had irregular shape, heterogeneous structure and sharp outlines. Color 
loci predominantly were along the contour of the tumor node. The spectrogram of blood flow in the 
tumor node characterised by low resistance and peripheral resistance: PSV – 11,4 cm/s; RI – 0,34; 
PI – 0,42 (Fig. 1). 
The spectrogram of blood flow in the uterine artery characterised by increased maximum 
systolic speed and low resistance index: PSV – 56,7 cm/s; RI – 0,52; PI – 1,22 (Fig. 2).
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Table 3
Clinical characteristics of patients undergoing planned hysterotomy
No.
Ser/No
Age, 
years Gravidity
Antecedent
Pregnancy
Prognostic score 
(FIGO)
Preoperative 
courses of  
chemo-therapy 
Operation type Size of tumour node, cm
1 27 1 Term 6 4 Hysterotomy 3,0
2 27 1 HM 8 4
Hysterotomy+
Thoracotomy+ 
resection of  
the bladder
4,0
3 28 2 Abortion 7 18 Hysterotomy 3,0
4 25 1 Abortion 9 5 Hysterotomy 3,0
5 32 5 HM 5 7 Hysterotomy 3,0
6 17 1 HM 6 11 Hysterotomy 2 nodes (each 2,5)
7 23 1 HM 6 8 Hysterotomy 2,5
8 22 1 HM 11 4 Hysterotomy 3,0
9 25 1 HM 7 7 Hysterotomy 2,5
10 26 1 HM 9 7 Hysterotomy 3,0
11 24 1 HM 10 9 Hysterotomy 3,0
12 27 1 HM 8 7 Hysterotomy 4,0
13 25 1 HM 9 6 Hysterotomy 3,5
Fig. 1. The spectrogram of blood flow in the tumor node
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Fig. 2. The spectrogram of blood flow in the uterine artery
Phases of the operation were similar for all patients of study group.
I. Removal of the tumor node, temporary shutdown of the uterine blood flow 
After laparotomy and revision of the pelvis and abdominal cavity on the ascending branches 
of uterine vessels on the right and left side of the uterus were imposed atraumatic clamps, tempo-
rarily muted the uterus from the circulation. The aim of this phase – to reduce intraoperative blood 
loss and prevent the dissemination of tumor cells. 
During the removal of the tumor nodes were used rational cuts, taking into account the 
topography of blood vessels, muscles and nerves of the uterus. Tumor nodes are removed only by a 
sharp, indented from the edge of tumors 0.5–1.0 cm, carried out extra careful hemostasis. 
II. Restoration of the uterine wall
The uterus was repaired in three layers with delayed-absorbable suture. After the main 
phase of the operation performed for 10 to 15 minutes, clamps are removed. 
III. Re-checked hemostasis 
Re-checked hemostasis after restoration of blood circulation in the uterus was done. If nec-
essary have been imposed additional seams on the uterus (Fig. 3). 
                                       a                                                                            b
Fig. 3. Hysterotomy with uterine reconstruction in patient with chemo-resistant trophoblastic 
tumour: a – scheme of the operation; b – uterus after reconstruction
 
 
Original Research Article:
full paper
(2017), «EUREKA: Health Sciences»
Number 3
61
Medicine and Dentistry
The basic condition of fertility-sparing hysterotomy with uterine reconstruction in patients 
with malignant trophoblastic tumours – minimal palpation of tumour node to reduce the risk of tu-
mour cells dissemination. If the lesion could not be seen, intraoperative ultrasound should be used.
There was no postoperative complication. Steady remission was observed in all cases. Follow-up 
period was 17 and 6 years after urgent and 1–12 years (on average 6.3 years) after planned surgery.
In 3 patients with chemotherapy – resistant GTN were multiple metastases to the lungs. 
So two of them were treated by adjuvant multiagent chemotherapy according to the protocol TP, 
one patient – by one cycles multiagent chemotherapy according to the protocol BEP (from further 
treatment patient refused). Steady remission in all cases. Follow- up varied from 5 to 7 years (on 
averaged 5.4 year).
5. Discussion
The issue concerning the uterus organ-preserving surgeries in malignant trophoblastic tu-
mors treatment has been little studied up to now.
There are few publications, describing urgent localized uterine resection, followed by uter-
ine reconstruction [6, 14–18]. The limited number of clinical observations is apparently caused by 
the fact that such treatment option was considered as wrong earlier. But now we know that fertil-
ity-sparing hysterotomy with excision of the tumour node (instead of hysterectomy) in an urgent 
way is possible even in the patients with a PSTT [15]. Physicians should therefore be aware of 
possible treatment alternatives to preserve fertility.
On the basis of the analysis of our own experience and the data of literature we have for-
mulated the following indications for the urgent fertility-sparing hysterotomy with uterine 
reconstruction in patients with malignant trophoblastic tumours: 
– solitary tumour node in myometrium (according to the data of radiological methods);
– absence of children in the family or strong desire to preserve fertility;
– young age of the patient.
Basic requirement of fertility-sparing treatment program is the beginning of chemotherapy 
in the early postoperative period.
Positive clinical practice of urgent hysterotomy in patients with malignant trophoblastic tu-
mours became a basis for the substantiation of possibility of analogous treatment option in patients 
with chemo-resistant and relapsed disease.
In determining the chemotherapy-resistant disease, we were guided by the same criteria that 
are formulated by F. Feng and Y. Xiang [19].
Definition of chemotherapy-resistant GTN and high-risk factors of drug resistance were: 
– plateau (less than for 50 %) of hCG level decrease;
– increase of hCG level (three consecutive measurements); 
– development of new metastases despite treatment;
high-risk factors of drug resistance:
– spread disease (metastatic site other than lung or vagina);
– the number of metastatic organs;
– the size of metastatic lesion being more than 3cm in diameter;
– prior unsuccessful chemotherapy;
– duration of disease greater than 4 month.
– According to the data, received out earlier in our institute [20], exists a positive correlation 
relationship between the level of hCG and the sizes of trophoblastic node in myometrium. In patients 
with chemotherapy-sensitive tumors, this correlation coefficient was r=0,88+0,09 (p<0,05) (Fig. 4).
In patients with chemotherapy-resistant tumors, this correlation coefficient was r=0,79+0,14 
(p<0,05) (Fig. 5). 
The necessity for chemotherapy after urgent operations is not in doubt. In patients with 
recurrent and chemotherapy-resistant disease levels of hCG normalized after tumor removal. Does 
adjuvant chemotherapy indicated for these patients? How many cycles? Clear answers to these 
questions are currently unavailable. 
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Fig. 4. Relative changes in the hCG level and the size of  
chemosensitive trophoblastic tumor in myometrium 
Fig. 5. Relative changes in the hCG level and the size of  
chemoresistant trophoblastic tumor in myometrium 
What should be the treatment strategy for patients with chemoresistant trophoblastic 
tumors after planned surgery? 
According to our previous data – the tumor tissue in myometrium is in necrosis in all cases. 
The volume of viable tumor tissue is only 2 % (Fig. 6).
However, according to the flow cytometry, the level of apoptosis was only 75 %. It was not 
possible to distinguish cells in apoptosis and necrotic cells by measurement of their DNA content 
by flow cytometry. But it was found that the remaining 25 % of tumor cells contain diploid amount 
of DNA with accessible S-phase fraction which was 14 %. 
Therefore, in the tumor remain cells with pathologic proliferative activity. Consequently, 
after the planned fertility-sparing hysterotomy with uterine reconstruction in patients with malig-
nant trophoblastic tumours adjuvant chemotherapy is mandatory until 8 weeks normal hCG levels.
After fertility-sparing hysterotomy with uterine reconstruction, myometrial structure in the 
projection of scar is inhomogeneous during 6 month. 3 month after operation angioarchitectonics 
of uterus is preserved.
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Fig. 6. Chemo-resistant trophoblastic tumor; operation material after uterine resection:  
1 – necrosis; 2 – fibrosis; 3 – hyalinosis of tumour tissue
Thus, fertility-sparing surgical treatment of patients with recurrent and chemotherapy- 
resistant postmolar GTN is possible even in metastatic disease. 
Some researchers have reported on the peculiarities of surgical treatment, taken at their Tro-
phoblastic centers. In Peking Union Medical College Hospital methotrexate was injected within the 
myometrium adjacent to surgical margins to minimize the possibility of inducing metastases [21]. 
Vasopressin was used to minimize bleeding and an argon-beam coagulator was used to evaporate 
the myometrium adjacent to the tumour without damaging the uterus in some centers [21]. We 
consider that adequate indentation from the edge of the tumor (0.5–1.0 cm) and extra careful hemo-
stasis in planned fertility-sparing surgery are enough. 
On the basis of the analysis of our own experience and the data of literature we have for-
mulated the following indications for the planned fertility-sparing hysterotomy with uterine 
reconstruction in patients with chemotherapy–resistant GTN: 
– absence of children in the family, strong desire to preserve fertility;
– young age of the patient;
– tumour node <4 cm or two adjacent tumour nodes (the same total size);
– serum hCG as low as possible.
Pregnancy in these patients is a high risk owing to possible uterine rupture caused by uterine 
scars [22], therefore these patients should be monitored closely in pregnancy by ultrasound assess-
ment of uterine thickness. 
6. Conclusion
1. Localized uterine resection with uterine reconstruction – the method of choice in malig-
nant trophoblastic tumours surgical treatment.
2. Fertility-sparing hysterotomy with uterine reconstruction is possible only in centers 
which are experienced in the complex multimodality treatment of GTN.
3. Basic requirement of fertility-sparing surgery is beginning adjuvant chemotherapy as 
soon as possible.
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Abstract
According to the data of the world statistics there is observed the continuous growth of chronic obstructive pulmonary 
disease (COPD). According to the last data of the World health organization (WHO), for today there is near 250 mln per-
sons with chronic obstructive pulmonary disease (COPD), and this disease becomes as cause of death of near 3 mln persons 
annually. 
Aim: to establish the prevalence of undiagnosed chronic pulmonary disease (COPD) among persons, who consider them-
selves as healthy ones and regularly undergo medical check-ups; to estimate the frequency of chronic obstructive pulmonary disease 
(COPD) according to the data of medical documentation. 
Methods and materials: 525 persons, older than 35, who did not have in an anamnesis any chronic diseases of respira-
tory tract, were interrogated. At the following stage, persons, who had taken 18 points or more underwent a spirography with 
bronchodilatation test, using 400 mcg of salbutamol and were interrogated by the modified questionnaire of short breath by 
the medical research council (MRC) and test of the chronic obstructive pulmonary disease estimation (COPD) (TEC). There 
were examined 136 patients, mean age (51,5±0,8), men were 81 (59,5 %) mean age (52,2±1,1) and women – 55 (40,4 %) mean 
age (50,7±0,9).
There were analyzed 56 medical stories of patients, treated at therapeutic departments of the city clinic because of internal 
organs diseases with the concomitant diagnosis of chronic obstructive pulmonary disease (COPD). 
Among persons with first revealed chronic obstructive pulmonary disease у 21 (26,6 %) was reveled І severity degree 
according to GOLD, in 26 persons (32,9 %) – GOLD ІІ, in 28 (35,4 %) – GOLD ІІІ, in 4 (5,1 %) – GOLD ІV severity degree, 
so 32 patients did not receive basic treatment at all. 
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